Study
|
Sample size (n)
|
HCV genotype (n)
|
End of treatment
|
End of follow-up
|
---|
| | | |
HCV ETVR (n)
|
ALT normalization (n)
|
HCV SVR (n)
|
HCV relapse (n)
|
ALT normalization (n)
|
---|
| |
Genotype 1
|
Non- genotype 1
|
Overall
|
Genotype 1
|
Non-genotype 1
| |
Overall
|
Genotype 1
|
Non-genotype 1
|
Overall
|
Genotype 1
|
Non-genotype 1
| |
---|
Yu et al. [35]
|
C: 50
|
30
|
20
|
46
|
27
|
19
|
NR
|
27
|
12
|
15
|
19
|
15
|
4
|
NR
|
|
M: 46
|
25
|
21
|
32
|
14
|
18
|
NR
|
26
|
11
|
15
|
6
|
3
|
3
|
NR
|
Liu et al. [32]
|
C: 161
|
97
|
64
|
138
|
82
|
56
|
NR
|
123
|
70
|
53
|
15
|
12
|
3
|
103
|
|
M: 160
|
110
|
50
|
141
|
95
|
46
|
NR
|
127
|
85
|
42
|
14
|
10
|
4
|
122
|
Chuang et al. [34]
|
C: 42
|
21
|
21
|
NR
|
NR
|
NR
|
NR
|
29
|
10
|
19
|
NR
|
NR
|
NR
|
23
|
|
M: 84
|
48
|
36
|
NR
|
NR
|
NR
|
NR
|
54
|
39
|
15
|
NR
|
NR
|
NR
|
51
|
Hung et al. [30]
|
C: 36
|
17
|
19
|
33
|
NR
|
NR
|
24
|
25
|
10
|
15
|
8
|
NR
|
NR
|
20
|
|
M: 72
|
34
|
38
|
68
|
NR
|
NR
|
66
|
51
|
18
|
33
|
17
|
NR
|
NR
|
52
|
Liu et al. [36]
|
C: 24
|
14
|
7
|
16
|
10
|
6
|
12
|
9
|
3
|
6
|
7
|
NR
|
NR
|
9
|
|
M: 30
|
17
|
13
|
25
|
NR
|
NR
|
23
|
18
|
NR
|
NR
|
5
|
NR
|
NR
|
18
|
- C HBV and HCV coinfection, M HCV mono-infection, NR not reported.